<code id='4988FE2780'></code><style id='4988FE2780'></style>
    • <acronym id='4988FE2780'></acronym>
      <center id='4988FE2780'><center id='4988FE2780'><tfoot id='4988FE2780'></tfoot></center><abbr id='4988FE2780'><dir id='4988FE2780'><tfoot id='4988FE2780'></tfoot><noframes id='4988FE2780'>

    • <optgroup id='4988FE2780'><strike id='4988FE2780'><sup id='4988FE2780'></sup></strike><code id='4988FE2780'></code></optgroup>
        1. <b id='4988FE2780'><label id='4988FE2780'><select id='4988FE2780'><dt id='4988FE2780'><span id='4988FE2780'></span></dt></select></label></b><u id='4988FE2780'></u>
          <i id='4988FE2780'><strike id='4988FE2780'><tt id='4988FE2780'><pre id='4988FE2780'></pre></tt></strike></i>

          Home / knowledge / leisure time

          leisure time


          leisure time

          author:Wikipedia    Page View:8
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In